Literature DB >> 24170542

Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells.

Min Fei1, Qinglei Hang, Sicong Hou, Songbin He, Changgeng Ruan.   

Abstract

Mounting evidence has been shown that integrin-mediated cellular adhesion confers resistance to chemotherapy of multiple myeloma. The molecular mechanism underlying cell adhesion-mediated drug resistance (CAM-DR) is, however, poorly understood. In this report, we demonstrated that RPMI 8,226 cells accumulated p27(Kip1) in the nucleus when they were adhered to fibronectin (FN). The adhesion-mediated p27(Kip1) nuclear recruitment was regulated via the down-regulation of Jab1, a negative regulator of cell cycle. Overexpression of Jab1 reversed the elevated p27(Kip1) in the nucleus, which needed phosphorylation of p27(Kip1) on Serine 10, whereas inhibition of Jab1 by siRNA further increased the elevated p27(Kip1). Furthermore, we found overexpression of Jab1 did not affect 8,226 cells adhesion to FN, but reversed doxorubicin or mitoxantrone-induced CAM-DR phenotype. In conclusion, our data suggest that Jab1 plays an important role in CAM-DR, which depends on pSer10-p27(Kip1)-mediated subcellular localization of p27(Kip1). The understanding of this novel molecular mechanism may prove valuable in designing new therapeutic approaches for CAM-DR in Multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24170542     DOI: 10.1007/s11010-013-1856-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  53 in total

Review 1.  Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle.

Authors:  S V Ekholm; S I Reed
Journal:  Curr Opin Cell Biol       Date:  2000-12       Impact factor: 8.382

Review 2.  COP9 signalosome revisited: a novel mediator of protein degradation.

Authors:  C Schwechheimer; X W Deng
Journal:  Trends Cell Biol       Date:  2001-10       Impact factor: 20.808

3.  Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.

Authors:  J Vlach; S Hennecke; B Amati
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

4.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1.

Authors:  K Tomoda; Y Kubota; J Kato
Journal:  Nature       Date:  1999-03-11       Impact factor: 49.962

Review 5.  The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer.

Authors:  J Tsihlias; L Kapusta; J Slingerland
Journal:  Annu Rev Med       Date:  1999       Impact factor: 13.739

6.  Multiple Myeloma: New Insights and Therapeutic Approaches.

Authors:  Kenneth C. Anderson; Robert A. Kyle; William S. Dalton; Terry Landowski; Kenneth Shain; Richard Jove; Lori Hazlehurst; James Berenson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2000

7.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

8.  Jun activation domain-binding protein 1 expression in malignant lymphoma of the thyroid: its linkage to degree of malignancy and p27 expression.

Authors:  Yasuhiro Ito; Hiroshi Yoshida; Fumio Matsuzuka; Nariaki Matsuura; Yasushi Nakamura; Hirokazu Nakamine; Kennichi Kakudo; Kanji Kuma; Akira Miyauchi
Journal:  Anticancer Res       Date:  2003 Sep-Oct       Impact factor: 2.480

9.  Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.

Authors:  Aiguo Shen; Yuchan Wang; Yueming Zhao; Lin Zou; Linlin Sun; Chun Cheng
Journal:  Neurosurgery       Date:  2009-07       Impact factor: 4.654

10.  Cancer statistics for Hispanics/Latinos, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012 Sep-Oct       Impact factor: 508.702

View more
  6 in total

1.  Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma.

Authors:  Xiaobing Miao; Xiaohong Xu; Yaxun Wu; Xinghua Zhu; Xudong Chen; Chunsun Li; Xiaoyun Lu; Yali Chen; Yushan Liu; Jieyu Huang; Yuchan Wang; Song He
Journal:  Tumour Biol       Date:  2015-08-23

Review 2.  Targeting E-selectin to Tackle Cancer Using Uproleselan.

Authors:  Barbara Muz; Anas Abdelghafer; Matea Markovic; Jessica Yavner; Anupama Melam; Noha Nabil Salama; Abdel Kareem Azab
Journal:  Cancers (Basel)       Date:  2021-01-18       Impact factor: 6.639

3.  Integrating Tumor Stroma Biomarkers With Clinical Indicators for Colon Cancer Survival Stratification.

Authors:  Yong Chen; Wenlong Wang; Bo Jiang; Lei Yao; Fada Xia; Xinying Li
Journal:  Front Med (Lausanne)       Date:  2020-12-07

4.  Biomimetic 3D Environment Based on Microgels as a Model for the Generation of Drug Resistance in Multiple Myeloma.

Authors:  Juan Carlos Marín-Payá; Blanca Díaz-Benito; Luis Amaro Martins; Sandra Clara Trujillo; Lourdes Cordón; Senentxu Lanceros-Méndez; Gloria Gallego Ferrer; Amparo Sempere; José Luis Gómez Ribelles
Journal:  Materials (Basel)       Date:  2021-11-23       Impact factor: 3.623

5.  Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells.

Authors:  Sophie Bustany; Jérôme Bourgeais; Guergana Tchakarska; Simon Body; Olivier Hérault; Fabrice Gouilleux; Brigitte Sola
Journal:  Oncotarget       Date:  2016-07-19

6.  Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma.

Authors:  Jing Liu; Yuchan Wang; Song He; Xiaohong Xu; Yuejiao Huang; Jie Tang; Yaxun Wu; Xiaobing Miao; Yunhua He; Qiru Wang; Li Liang; Chun Cheng
Journal:  Hematology       Date:  2016-06-18       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.